Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 05 - 12 tags : Phase 2 save search
Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
Published: 2021-05-12 (Crawled : 20:00) - celyad.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: 11.11%
H: 1.69%
C: -2.71%
europe phase 1 trial phase 3 phase 2 car-t
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021
Published: 2021-05-12 (Crawled : 17:00) - biospace.com/
PTGX | $25.22 -1.37% -1.35% 430K
|
Health Technology
|
| O: -1.8%
H: 8.91%
C: 1.07%
presentation phase 2 results
Clene Nanomedicine Presents Updated Blinded Efficacy Data from Ongoing Phase 2 RESCUE-ALS Study at the ENCALS 2021 Annual Meeting
Published: 2021-05-12 (Crawled : 13:00) - globenewswire.com
CLNN S | $0.3299 -2.86% -3.69% 1.2M
|
|
| O: 4.53%
H: 1.12%
C: -2.89%
phase 2 ongoing als
GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates
Published: 2021-05-12 (Crawled : 13:00) - biospace.com/
GTBP | $3.8001 -4.28% 1.3% 1K
|
Manufacturing
|
| O: -0.4%
H: 1.93%
C: -14.03%
phase 2 biopharma therapy trial solid tumors
Ocuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia
Published: 2021-05-12 (Crawled : 12:15) - biospace.com/
OCUP | $1.67 -4.02% -3.88% 240K
|
Health Technology
|
| O: -1.85%
H: 3.29%
C: 2.12%
treatment phase 2 trial enroll presbyopia
Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data
Published: 2021-05-12 (Crawled : 12:00) - biospace.com/
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: -0.44%
H: 1.27%
C: -1.14%
stroke phase 2 positive drug phase 2b
BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis
Published: 2021-05-12 (Crawled : 06:00) - globenewswire.com
BPTS | News | $0.326 12.26% 11.73% 340K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 covid
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.